Rabbit Recombinant Monoclonal Muscarinic Acetylcholine Receptor 2/CM2 antibody - conjugated to PE.
IgG
Rabbit
PE
Ex: 480;565nm, Em: 578nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Liquid
Monoclonal
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol.
Muscarinic acetylcholine receptor M2, CHRM2
Rabbit Recombinant Monoclonal Muscarinic Acetylcholine Receptor 2/CM2 antibody - conjugated to PE.
IgG
Rabbit
PE
Ex: 480;565nm, Em: 578nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Liquid
Monoclonal
EPR4568
Affinity purification Protein A
Please note: blast analysis of the immunogen sequence for ab109226 shows 64% homology with the Muscarinic Acetylcholine Receptor 3, therefore some reactivity with this receptor subtype may be possible.
Blue Ice
1-2 weeks
+4°C
+4°C
Upon delivery aliquot
Avoid freeze / thaw cycle, Store in the dark
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
This supplementary information is collated from multiple sources and compiled automatically.
Muscarinic Acetylcholine Receptor 2 (M2) also known as CHRM2 is a G protein-coupled receptor (GPCR) with a molecular mass of about 66 kDa. This receptor is predominantly expressed in cardiac tissue particularly in the atria and plays a fundamental role in the parasympathetic nervous system by mediating the effects of acetylcholine. M2 receptors participate in negative feedback control by inhibiting adenylate cyclase which reduces the conversion of ATP to cAMP affecting heart rate and contractility. These receptors are an important target for anti-muscarinic agents like otenzepad and AF-DX 116 which inhibit the receptor's activity.
Muscarinic acetylcholine receptors perform diverse functions participating in the regulation of autonomic nervous system responses. M2 receptors are not part of a large protein complex but function closely with other GPCRs to maintain homeostasis. They modulate the activity of various ion channels contributing to their role in cardiac physiological processes. Anti-muscarinic antibodies can specifically target M2 for therapeutic interventions which further helps in dissecting their biological functionality.
M2 receptors play essential roles in both the autonomic nervous system and the cardiovascular system. They are involved in the cholinergic signaling pathway which modulates heart rate by influencing ion channel activity and reducing intracellular cAMP levels. Their interaction with proteins like G-proteins and ion channels such as Kir3.1 underlines their importance in these pathways. M2 muscarinic receptors are closely linked with other muscarinic receptors showing a collaborative action in signaling cascades.
M2 receptors have connections with cardiovascular diseases and certain neurological disorders. Alterations in M2 receptor function or expression can lead to conditions like bradycardia where the heart rate is abnormally slow and are also implicated in cognitive disorders linked to cholinergic dysfunction. The receptor's interaction with other muscarinic receptors like M1 and M4 further ties it to these pathologies amplifying its relevance in understanding complex diseases. Anti-muscarinic antibodies targeting M2 can modulate these interactions offering potential therapeutic benefits.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com